Logo

Merck Terminates Development and Commercialization Deal with Samsung Bioepis for Lusduna Nexvue (insulin glargine)

Share this

Merck Terminates Development and Commercialization Deal with Samsung Bioepis for Lusduna Nexvue (insulin glargine)

Shots:

  • The termination of 2014 deal with Samsung- is the result of Lusduna Nexvue’s sales and production costs. Samsung receives $155M as total termination cost including investment and interest on it from Merck
  • The collaboration is response to the agreement in 2013 among Merck- Samsung Biologics and Samsung Bioepis to develop multiple biosimilar candidates across therapeutic areas
  • Lusduna Nexvue 100mg is a pre-filled device and received tentative approval from the US FDA indicated to treat diabetes

Ref: Merck | Image: Merck


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions